- ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
- Aptose Presents Highlights from Clinical Update
- AstraZeneca showcases scientific advances across rare and malignant haematological conditions
- BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline
- CARVYKTI (ciltacabtagene autoleucel; cilta-cel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study
- Cellectis Presents Updated Clinical and Translational Data on BALLI-01
- Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas
- Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma, Highlighting 100% ORR
- Gilteritinib as Maintenance Therapy Demonstrated Benefit in Subgroups of FLT3-ITD AML Patients
- HUTCHMED Highlights Presentations for Hematological Malignancy Programs
- Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML
- Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program
- Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib
- Nkarta Presents NKX019 Clinical Data
- Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120
- Servier Presents Updated Results for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Relapsed/Refractory Myelodysplastic Syndromes